Status In progress
Process CDF Review
ID number 2727

Provisional Schedule

Committee meeting: 2 06 July 2021
Expected publication 15 September 2021

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Eli Lilly and Company Ltd.
Others Department of Health and Social Care
  NHS England & Improvement
  Welsh Government
Patient carer groups Breast Cancer Now
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Breast Cancer Group


Comparator companies Pfizer
  Zentiva (a Sanofi company)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
12 February 2021 - 05 March 2021 Appraisal consultation
05 January 2021 Committee meeting: 1
26 August 2020 Invitation to participate
17 June 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance